Cargando…

Dual targeting of HER3 and MEK may overcome HER3-dependent drug-resistance of colon cancers

Although the medical treatment of colorectal cancer has evolved greatly in the last years, a significant portion of early-stage patients develops recurrence after therapies. The current clinical trials are directed to evaluate new drug combinations and treatment schedules. By the use of patient-deri...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bon, Giulia, Loria, Rossella, Amoreo, Carla Azzurra, Verdina, Alessandra, Sperduti, Isabella, Mastrofrancesco, Arianna, Soddu, Silvia, Diodoro, Maria Grazia, Mottolese, Marcella, Todaro, Matilde, Stassi, Giorgio, Milella, Michele, De Maria, Ruggero, Falcioni, Rita
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5752456/ https://www.ncbi.nlm.nih.gov/pubmed/29312543 http://dx.doi.org/10.18632/oncotarget.11400

Ejemplares similares

MKK3 sustains cell proliferation and survival through p38DELTA MAPK activation in colorectal cancer
por: Stramucci, Lorenzo, et al.
Publicado: (2019)

Apoptosis induced by a HIPK2 full-length-specific siRNA is due to off-target effects rather than prevalence of HIPK2-Δe8 isoform
por: Di Rocco, Giuliana, et al.
Publicado: (2015)

SEMA6A/RhoA/YAP axis mediates tumor-stroma interactions and prevents response to dual BRAF/MEK inhibition in BRAF-mutant melanoma
por: Loria, Rossella, et al.
Publicado: (2022)

HMGA1/E2F1 axis and NFkB pathways regulate LPS progression and trabectedin resistance
por: Loria, Rossella, et al.
Publicado: (2018)

Targeting HER3 or MEK overcomes acquired Trastuzumab resistance in HER2-positive gastric cancer-derived xenograft
por: Zhang, Mengqi, et al.
Publicado: (2022)

Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study
por: Bon, Giulia, et al.
Publicado: (2020)

HER3 expression and MEK activation in non-small-cell lung carcinoma
por: Manickavasagar, Thubeena, et al.
Publicado: (2021)

PI3K-driven HER2 expression is a potential therapeutic target in colorectal cancer stem cells
por: Mangiapane, Laura Rosa, et al.
Publicado: (2022)

BRAF status modulates Interelukin-8 expression through a CHOP-dependent mechanism in colorectal cancer
por: Conciatori, Fabiana, et al.
Publicado: (2020)

HER kinase inhibition in patients with HER2- and HER3-mutant cancers
por: Hyman, David M., et al.
Publicado: (2018)

Role of gonadotropin-releasing hormone analogues in metastatic male breast cancer: results from a pooled analysis
por: Di Lauro, Luigi, et al.
Publicado: (2015)

PTEN status is a crucial determinant of the functional outcome of combined MEK and mTOR inhibition in cancer
por: Milella, Michele, et al.
Publicado: (2017)

Cytogenetic analysis of HER1/EGFR, HER2, HER3 and HER4 in 278 breast cancer patients
por: Sassen, Andrea, et al.
Publicado: (2008)

The role of HER2 and HER3 in HER2-amplified cancers beyond breast cancers
por: Majumder, Avisek, et al.
Publicado: (2021)

HER-3 expression in HER-2-amplified breast carcinoma
por: Czopek, Jacek, et al.
Publicado: (2013)

Model-Based Analysis of HER Activation in Cells Co-Expressing EGFR, HER2 and HER3
por: Shankaran, Harish, et al.
Publicado: (2013)

TRF2 and VEGF-A: an unknown relationship with prognostic impact on survival of colorectal cancer patients
por: Dinami, Roberto, et al.
Publicado: (2020)

HER2 Status Determination: Analyzing the Problems to Find the Solutions
por: Terrenato, Irene, et al.
Publicado: (2015)

Novel agents that downregulate EGFR, HER2, and HER3 in parallel
por: Ferreira, Renan Barroso, et al.
Publicado: (2015)

Overexpression of HER2/HER3 and clinical feature of ovarian cancer
por: Chung, Ye Won, et al.
Publicado: (2019)

Mutant HER2 needs mutant HER3 to be an effective oncogene
por: Trenker, Raphael, et al.
Publicado: (2021)

Assessment of HER2 Protein Overexpression and Gene Amplification in Renal Collecting Duct Carcinoma: Therapeutic Implication
por: Costantini, Manuela, et al.
Publicado: (2020)

The relation between survival and expression of HER1 and HER2 depends on the expression of HER3 and HER4: a study in bladder cancer patients
por: Memon, A A, et al.
Publicado: (2006)

Novel association of DJ-1 with HER3 potentiates HER3 activation and signaling in cancer
por: Zhang, Shu, et al.
Publicado: (2016)

Targeting HER proteins in cancer therapy and the role of the non-target HER3
por: Hsieh, A C, et al.
Publicado: (2007)

Prognostic significance of HER3 and HER4 protein expression in colorectal adenocarcinomas
por: Kountourakis, Panteleimon, et al.
Publicado: (2006)

HER-2 and HER-3 expression in liver metastases of patients with colorectal cancer
por: Styczen, Hanna, et al.
Publicado: (2015)

Single-molecule functional anatomy of endogenous HER2-HER3 heterodimers
por: Choi, Byoungsan, et al.
Publicado: (2020)

HER3, p95HER2, and HER2 protein expression levels define multiple subtypes of HER2-positive metastatic breast cancer
por: Lipton, Allan, et al.
Publicado: (2013)

Patritumab deruxtecan (HER3-DXd), a novel HER3 directed antibody drug conjugate, exhibits in vitro activity against breast cancer cells expressing HER3 mutations with and without HER2 overexpression
por: Koyama, Kumiko, et al.
Publicado: (2022)

Correlation of HER2, p95HER2 and HER3 Expression and Treatment Outcome of Lapatinib plus Capecitabine in her2-Positive Metastatic Breast Cancer
por: Han, Sae-Won, et al.
Publicado: (2012)

Phase Ib study evaluating safety and clinical activity of the anti-HER3 antibody lumretuzumab combined with the anti-HER2 antibody pertuzumab and paclitaxel in HER3-positive, HER2-low metastatic breast cancer
por: Schneeweiss, Andreas, et al.
Publicado: (2018)

Targetable HER3 functions driving tumorigenic signaling in HER2-amplified cancers
por: Campbell, Marcia R., et al.
Publicado: (2022)

Extensive conformational and physical plasticity protects HER2-HER3 tumorigenic signaling
por: Campbell, Marcia R., et al.
Publicado: (2022)

Extensive conformational and physical plasticity protects HER2-HER3 tumorigenic signaling
por: Campbell, Marcia R., et al.
Publicado: (2022)

HER-3: hub for escape mechanisms
por: Capone, Emily, et al.
Publicado: (2015)

Pharmacological Targeting of the Pseudokinase Her3
por: Xie, Ting, et al.
Publicado: (2014)

A phase I trial of the pan-ERBB inhibitor neratinib combined with the MEK inhibitor trametinib in patients with advanced cancer with EGFR mutation/amplification, HER2 mutation/amplification, HER3/4 mutation or KRAS mutation
por: Piha-Paul, Sarina A., et al.
Publicado: (2023)

Axonal Neuregulin Signals Cells of the Oligodendrocyte Lineage through Activation of HER4 and Schwann Cells through HER2 and HER3
por: Vartanian, Timothy, et al.
Publicado: (1997)

Protein secretion in human mammary epithelial cells following HER1 receptor activation: influence of HER2 and HER3 expression
por: Zhang, Yi, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_himtohpdngc522nrno1ucfaiaf